• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Petrelli F Vavassori I Coinu A et al


    [19] Petrelli F, Vavassori I, Coinu A, et al. Radical prostatectomy or radio-therapy in high-risk prostate cancer: RVX-208 systematic review and meta-analysis. Clin Genitourin Cancer 2014;12:215–24.
    [20] Yossepowitch O, Eggener SE, Bianco FJ Jr, et al. Radical prostatec-tomy for clinically localized, high risk prostate cancer: critical analy-sis of risk assessment methods. J Urol 2007;178:493–9.
    [21] Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data-content, research application and generalizability to the United States elderly population. Medical Care 2002;40(suppl) (IV):3–18.
    [22] Bratt O, Folkvaljon Y, Hj€alm Eriksson M, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol 2015;68(1):53–8.
    [24] Spreeuwenberg MD, Bartak A, Croon MA, et al. The multiple pro-pensity score a control for bias in the comparison of more than two treatment arms-an introduction from a case study in mental health. Med Care 2010;48:166–74.
    [25] Johnston MK, Gustafson P, Levy AR, et al. Use of instrumental variables in the analysis of generalized linear models in the presence of unmea-sured confounding with applications to epidemiological research. Stat Med 2008;27:1539–656.
    [26] Cooperberg MR, Vickers AJ, Broering JM, et al. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010;116(22):5226–34.
    [27] Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol 2014;15:223–31.
    [29] Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-spe-cific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300–5.
    [30] Mossanena M, Nepple KG, Grubb RL 3rd, et al. Heterogeneity in def-initions of high-risk prostate cancer and varying impact on mortality rates after radical prostatectomy. Eur Urol Oncol 2018;1(2):143–8.
    [31] Yossepowitch O, Eastham JA. Radical prostatectomy for high-risk prostate cancer. World J Urol 2008;26:219–24. Accepted Manuscript
    Comparative Effectiveness Study of Face-to-Face and Teledermatology Workflows for Diagnosing Skin Cancer
    To appear in: Journal of the American Academy of Dermatology
    Please cite this article as: Marwaha S, Fevrier H, Alexeeff S, Crowley E, Haiman M, Pham N, Tuerk M, Wukda D, Hartmann M, Herrinton L, Comparative Effectiveness Study of Face-to-Face and Teledermatology Workflows for Diagnosing Skin Cancer, Journal of the American Academy of Dermatology (2019), doi:
    This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before Mb is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
    Comparative Effectiveness Study of Face-to-Face and Teledermatology Workflows
    for Diagnosing Skin Cancer
    MD, Wukda D7, Hartmann M7, Herrinton LJ2 PhD
    Affiliations: 1Dermatology, Kaiser Permanente, Sacramento, CA; 2 Division of Research, Kaiser Permanente, Oakland;
    CA; 3 Dermatology, Kaiser Permanente, Vallejo, CA; 4 Dermatology, Kaiser Permanente, Santa Rosa CA; 5 Dermatology,
    Kaiser Permanente, Santa Clara, CA; 6 Dermatology, Kaiser Permanente, Walnut Creek, CA; 7 The Permanente Medical Group, Quality and Operations Support, Kaiser Permanente, Oakland CA.
    Corresponding Author: Lisa Herrinton, PhD. Division of Research, 2000 Broadway, Oakland, CA 94612; email:
    Funding Sources: This research was funded solely by The Permanente Medical Group, Rapid Analytics Unit.
    Role of Study Sponsor: The funder had no role after making a funding decision. They did not write the research plan, participate in data collection, analyze the data, interpret the findings, or review the manuscript. Conflict of Interest: The authors report no conflicts of interest.
    Publications: This manuscript has not been previously published or presented.
    Reprint: No reprints are requested.
    Brief Title: Teledermatology Outcomes
    Keywords: Comparative Effectiveness Research; Telemedicine; Skin Cancer; Dermatology/diagnosis; Dermatology/epidemiology; Dermatology/organization and administration. List of Attachments: Research protocol and statistical analysis plan.